Culturing PBMCs with overlapping peptides derived from the sequence of the tumor antigen and IL-2 plus IL-15 prior to analysis by flow cytometry or ELISPOT assay appears to be quite sensitive, but can also induce false positives by stimulating naive T cells. Direct ex vivo methods appear to not be sensitive enough and the use of labeled multimers is limited by HLA type and the ability to identify epitopes.

Similar questions and discussions